212 related articles for article (PubMed ID: 10337721)
1. Development of a new prevention maintenance therapy for postmenopausal women.
Jordan VC
Recent Results Cancer Res; 1999; 151():96-109. PubMed ID: 10337721
[TBL] [Abstract][Full Text] [Related]
2. The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer.
Overmoyer BA
Cleve Clin J Med; 1999 Jan; 66(1):33-40. PubMed ID: 9926629
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
4. Prevention of breast cancer in high-risk women.
Kardinal CG; Veith R
J La State Med Soc; 1999 Apr; 151(4):198-201. PubMed ID: 10234895
[TBL] [Abstract][Full Text] [Related]
5. Status of antiestrogen breast cancer prevention trials.
Powles TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen for prevention of breast cancer.
Med Lett Drugs Ther; 1999 Jan; 41(1043):1-2. PubMed ID: 9924486
[No Abstract] [Full Text] [Related]
7. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
8. Overview of the main outcomes in breast-cancer prevention trials.
Cuzick J; Powles T; Veronesi U; Forbes J; Edwards R; Ashley S; Boyle P
Lancet; 2003 Jan; 361(9354):296-300. PubMed ID: 12559863
[TBL] [Abstract][Full Text] [Related]
9. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
Cummings SR; Eckert S; Krueger KA; Grady D; Powles TJ; Cauley JA; Norton L; Nickelsen T; Bjarnason NH; Morrow M; Lippman ME; Black D; Glusman JE; Costa A; Jordan VC
JAMA; 1999 Jun; 281(23):2189-97. PubMed ID: 10376571
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
11. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer prevention trials.
Rhodes DJ; Hartmann LC; Perez EA
Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893
[TBL] [Abstract][Full Text] [Related]
13. Selective estrogen-receptor modulators in 2001.
O'Regan RM; Gradishar WJ
Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of antiestrogens for prevention of breast cancer.
Reddy P; Chow MS
Am J Health Syst Pharm; 2000 Jul; 57(14):1315-22; quiz 1323-5. PubMed ID: 10918921
[TBL] [Abstract][Full Text] [Related]
15. Designer estrogens.
Jordan VC
Sci Am; 1998 Oct; 279(4):60-7. PubMed ID: 9768522
[No Abstract] [Full Text] [Related]
16. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
17. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
[TBL] [Abstract][Full Text] [Related]
18. Anti-estrogens come of age: a pioneer looks back.
Nelson NJ
J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
[No Abstract] [Full Text] [Related]
19. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Runowicz CD; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Ford LG; Vogel VG; Wolmark N
Am J Obstet Gynecol; 2011 Dec; 205(6):535.e1-5. PubMed ID: 21872200
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]